Table 2 Exclusion criteria of included studies
Author | Year | Exclusion Criteria | |
|---|---|---|---|
Factors affecting inflammatory status | Coexisting lesions (pelvic pathological conditions) | ||
Cho | 2008 | _ | Adenomyosis or clinical suspicion of leiomyoma |
Hua | 2013 | Hematemesis, immune system diseases, pregnancy, abnormal liver function, tuberculosis, endocrine disease, pelvic inflammatory disease | Adenomyosis, leiomyoma |
Sayan | 2013 | Use of hormonal medications during the 6 months prior to the laparoscopy, pregnancy, presence of chronic or acute inflammation and autoimmune disease, a presentation of pelvic inflammatory disease (PID) | Adenomyosis, leiomyoma, ovarian neoplasia |
Yavuzcan | 2013 | Pelvic inflammatory disease, borderline ovarian tumor, patients with infectious disease, smokers, chronic or acute inflammatory disease, systemic disorder or autoimmune, malignancy | Endometrial hyperplasia, endometrial polyp, adenomyosis, myoma uteri, gynecological malignancy, benign adnexal mass |
Tokmak | 2015 | Metabolic and autoimmune disorders, chronic inflammatory disease, or malignancy, current acute infection, inflammatory disease | Myoma uteri, adenomyosis, endometrial pathology |
Li | 2016 | Malignant tumor, acute inflammation, and patients with severe endocrine disorder, patients received hormone or other endocrine therapy in three months, patients with severe underlying disease (severe kidney, liver, heart dysfunction) | Uterine glandular myopathy or uterine leiomyoma |
Vigano | 2017 | Malignancy, taken antiplatelet drugs, steroid hormones, oral contraceptives, or other medications in the last 3 months before surgery | _ |
Seckin | 2018 | History of hormonal therapy, pregnancy, malignancy, acute infection, immune system and hematologic disorders, abnormal liver function, chronic inflammatory disease, current pelvic inflammatory disease | Gynecological malignancy, myoma uteri and adenomyosis, adnexal torsion or ruptured ovarian cysts |
Kalem | 2020 | Receiving steroid or estrogen and/or progesterone, pregnancy, pelvic-systemic infection | Preoperative cyst rupture |
Turgut | 2019 | Smoking, pregnancy, hormonal treatment, menopause, chronic diseases (connective tissue disorders, hematological, hypertension, cardiac, kidney or liver diseases, diabetes mellitus or prediabetes, asthma, hyperlipidemia), neoplastic disease, previous thrombosis, use of glucocorticoids, acute chronic inflammatory disorders, anticoagulants, antineoplastic agents, oral contraceptives, non-steroidal anti-inflammatory drugs | Endometrial pathology, adenomyosis, leiomyoma |
Tas | 2019 | Autoimmune disorders, smoking, malignancy, hematological disease, diabetes, cardiovascular disease, advanced liver or kidney disease, acute or chronic inflammatory diseases, acute infectious disease within the last 3 months | _ |
Biyik | 2020 | Active infections, hormone-releasing tumor, autoimmune disease, inflammatory disease, dyslipidemia, cancer, diabetes, cardiovascular disease), patients using (dyslipidemia drug oral contraceptive, gonadotropin hormone releasing hormone analogue, dienogest, antihypertensive, antiplatelet drug, antidiabetic drug, steroid, anticoagulant) | _ |
Karadadas | 2020 | malignancy, pregnancy, history of endometriosis, known chronic or acute inflammation | _ |
Moini | 2020 | moking, infectious diseases, any malignancies, acute or chronic inflammatory diseases | Polyp or malignant ovarian tumors, uterine myoma, adenomyosis, endometrial hyperplasia, pelvic inflammatory disease |
Ottolina | 2020 | Autoimmune diseases, coagulation disorders, concomitant anticoagulant therapy or use of antiplatelet at the time of surgery | Ovarian or uterine malignancy, |
Chen,T | 2021 | Taking any hormone drugs, complicated with other endocrine or metabolic or immune diseases, having a history of pregnancy within 6 months, malignant tumors | Uterine leiomyoma and adenomyosis |
Chen,Z | 2021 | Acute inflammation, malignancy, metabolic diseases, suspected infectious disease, autoimmune disease, oral contraceptives, Hormonal therapy, pregnancy, gonadotropin-releasing hormone analogs, or any other hormonal treatment, hemostatic agents and herbal compounds and antithrombotic | Abnormal uterine bleeding in the previous, |
Kedzia | 2021 | An uncertain family history of thrombosis, neoplasm, a prior episode of thrombosis diagnosed as acquired or inherited thrombophilia | _ |